Instead of spinning sperm in a centrifuge, EVA lets the cells select themselves — by responding to the same cues that guide them toward the egg. Each project added one of those cues to EVA's design and evidence base.
On the journey to the egg, sperm read a series of physical and chemical signals. EVA recreates them, so the most capable cells reveal themselves — no centrifugation.
Swimming against a fluid current — only the strong hold their course.
Swimming up a temperature gradient toward the warmer site of fertilisation.
Following surfaces and channel walls, the way sperm hug the tract's contours.
Following chemical signals the egg releases as sperm draw near.
Six funded projects, each building on the last — grounded in EU records and project reports. Outcomes are stated qualitatively, pending peer-reviewed publication.
Every selection method starts with one question: what does a good swimmer actually look like? MicroFSMA built a platform to observe that behaviour directly — employing microfluidics to study sperm navigation while varying the flow conditions and temperature settings, turning a subjective, manual assessment into an objective read-out, cell by cell. It became the measurement foundation for everything that followed.
EVA's first test beyond the bench. With a partner reproductive-biology laboratory, the first prototype was benchmarked head-to-head against the clinical standard — density-gradient centrifugation — across human samples ranging from normal to challenging low-count cases. EVA recovered a subpopulation of exceptionally high quality, and hands-on clinical feedback set the agenda for the next stage.
Dr. Shiva Kant ShuklaPrincipal Investigator
If RSM proved EVA selects the best sperm, Inno R&D set out to recover enough of them — without giving up that quality. By adding a third natural cue, thigmotaxis, and validating concepts through fluid-dynamics simulation rather than trial-and-error, the project lifted throughput while preserving the near-perfect quality EVA had shown. Carried out in Beezbiotech's own micro-fabrication lab at the Biopôle in Rennes.
Dr. Shiva Kant ShuklaPrincipal Investigator
Fertilisation isn't only a race for the fastest swimmer — the egg actively releases chemical signals that guide sperm toward it. MicroBeaCh studies that fourth cue, chemotaxis, pairing a platform that reproduces physiological chemical gradients with AI-powered vision that tracks flagellar motion in real time. The aim: identify new markers of true fertilising capability.
With the science established, EVA is measured against the methods clinics rely on today, in real commercial conditions. The goal is comparative, decision-grade evidence — how EVA's self-selected sperm performs beside conventional techniques on the outcomes embryologists care about, and how it fits a working lab's day. This is the evidence that turns clinical interest into adoption.
A device can work in one lab and still not be ready for the world. This programme manufactures production-representative batches and evaluates them across multiple centres, demonstrating the two things routine clinical use demands: reproducibility and consistency at scale. It is also the evidence base behind CE marking under EU MDR — performance shown reliably, across batches and independent sites.
Validation, adoption, and intelligence are not separate bets — they are the same bet, sequenced. Each unlocks the next, and together they compound toward a single outcome: more cycles that end in a healthy birth.
the year we aim to have doubled assisted-reproduction success rates.
Clinics, researchers, and investors who want to move this roadmap faster — we would like to talk.
